文献速递白血病

风险适配的苯达莫司汀联合利妥昔单抗是老年慢性淋巴细胞白血病可耐受的治疗选择:一项基于141例连续瑞典患者的区域真实世界报告

Risk-adapted bendamustine + rituximab is a tolerable treatment alternative for elderly patients with chronic lymphocytic leukaemia: a regional real-world report on 141 consecutive Swedish patients.
PubMed 文献 · Br J Haematol · 2020-08-10

这项回顾性真实世界研究分析了斯德哥尔摩地区2007至2016年诊断的141例接受苯达莫司汀联合利妥昔单抗(BR)作为一线(n=84)或后续线(n=57)治疗的慢性淋巴细胞白血病(CLL)患者。中位年龄72岁,49%为Binet C期,40%的累积疾病评定量表(CIRS)评分≥6,20%的东部肿瘤协作组(ECOG)评分为2,无del(17p)患者。结果显示BR在≥80岁患者中也可耐受,只要采用仔细调整的剂量,其疗效和安全性与其他较年轻患者相似。

要点

  • ≥80岁患者中仅15%接受全剂量苯达莫司汀,65%将利妥昔单抗推迟至第2周期。
  • 总体缓解率一线为83%,后续线为67%(P<0.022),在各年龄亚组间分布均等。
  • 多因素分析中ECOG评分、IGHV突变状态和细胞遗传学是PFS的显著影响因素,治疗线和年龄则不是。

核心结论

  • BR在≥80岁患者中也可耐受,只要采用仔细调整的剂量,其疗效和安全性与其他较年轻患者相似。

研究设计与样本

  • 回顾性真实世界研究,纳入斯德哥尔摩地区2007至2016年诊断的141例CLL患者,均接受BR作为一线(n=84)或后续线(n=57)治疗。

主要发现

  • 中位年龄72岁,49%为Binet C期,40%的CIRS评分≥6,20%的ECOG评分为2,无del(17p)患者。
  • ≥80岁患者中仅15%接受全剂量苯达莫司汀,65%将利妥昔单抗推迟至第2周期;73-79岁患者中对应比例为21%和36%;<73岁患者中为63%和33%。
  • 总体缓解率一线为83%,后续线为67%(P<0.022),在各年龄亚组间分布均等。
  • 多因素分析中ECOG评分、IGHV突变状态和细胞遗传学是PFS的显著影响因素,治疗线和年龄则不是。
  • 感染和中性粒细胞减少/血小板减少(≥3级)在各年龄亚组间相似。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Bendamustine + rituximab (BR) is the current first-line standard-of-care for chronic lymphocytic leukaemia (CLL) in fit patients aged 66-70 years, whereas chlorambucil + CD20 antibody is recommended in older patients with co-morbidities. This retrospective real-world study investigated whether risk-adapted BR was safe and effective in elderly patients. All 141 CLL patients in the Stockholm region (diagnosed from 2007 to 2016, identified from regional registries) who had received BR as first (n = 84) or later line (n = 57) were analysed. Median age was 72 years, 49% had Binet stage C, 40% had Cumulative Illness Rating Scale (CIRS) score ≥ 6, 20% Eastern Cooperative Oncology Group (ECOG) score 2. None had del(17p). Only 15% of patients aged ≥80 years received full-dose bendamustine and 65% of them postponed rituximab until cycle 2. Corresponding numbers in patients 73-79 years were 21% and 36% and in <73 years, 63% and 33%. Overall response rate was 83% (first line) and 67% (later line) (P < 0·022) equally distributed between age subsets. ECOG, immunoglobulin heavy chain variable region (IGHV) mutational status and cytogenetics, but not treatment line and age, were significant factors on progression-free survival (PFS) in multivariate analysis. Infections and neutropenia/thrombocytopenia (≥grade 3) were similar across age subgroups. In summary, BR was well tolerated even in patients ≥80 years, with similar efficacy and safety as in less old patients, provided that carefully adapted dosing was applied.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Mattsson A, Sylvan SE, Asklid A, et al. Risk-adapted bendamustine + rituximab is a tolerable treatment alternative for elderly patients with chronic lymphocytic leukaemia: a regional real-world report on 141 consecutive Swedish patients. Br J Haematol. 2020. PMID: 32779190. doi:10.1111/bjh.17032

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。